← All comparisons
Head-to-head · FAERS comparison

Abatacept vs Ipilimumab: side effects in FDA adverse event reports

How to read this page. FAERS report counts have no denominator; the comparison is of reporting patterns, not of risk. Signals are screened against each FDA label (badges) but not causally assessed. Not medical advice.

At a glance

AbataceptIpilimumab
Drug classSelective T Cell Costimulation ModulatorCTLA-4-directed Blocking Antibody
Brand namesOrenciaYervoy
FAERS reports137,36742,905
Serious60%89%
Death outcome9,2399,586
Boxed warningNoNo

Signals both drugs share

No strong shared signal after removing coding and lab terms.

Labeled signals distinctive to Abatacept

  • None stood out among the strongest labeled signals.

Labeled signals distinctive to Ipilimumab

Common questions

Which has more reported side effects, Abatacept or Ipilimumab?

Abatacept has 137,367 FAERS reports and Ipilimumab 42,905. More reports does not mean more dangerous: volume follows how widely and how long a drug has been used, prescription vs over-the-counter status, and publicity. The seriousness share (60% vs 89%) is a better like-for-like signal of the kind of problems reported.

Which side effects do Abatacept and Ipilimumab share?

They share no strong flagged signal after artifacts and lab terms are removed.

Is Abatacept or Ipilimumab safer?

FAERS cannot answer that: it has no denominator and no comparator. Use this page to see which risks are already on each label and which signals are unlabeled, then check the prescribing information and your clinician for your situation.

Sources: openFDA FAERS pair statistics (OpenPV build 2026-09-14), FDA labels via openFDA, openFDA count queries for seriousness and deaths. Pair chosen because it is a commonly searched comparison. Generated 2026-10-08.